{"id":3828,"date":"2018-12-18T15:31:26","date_gmt":"2018-12-18T10:01:26","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3828"},"modified":"2021-07-24T12:57:09","modified_gmt":"2021-07-24T07:27:09","slug":"notizia-84","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-84","title":{"rendered":"HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer\u2019s; Bristol-Myers, H3 Biomedicine discover RNA splicing"},"content":{"rendered":"\n

HER2 Vaccine Candidate Meet Phase 1b Study <\/strong><\/p>\n\n\n\n

An Australian biotech company<\/strong> stated its Human Epidermal Growth Factor Receptor 2 (HER2)<\/strong> vaccine candidate, HER-Vaxx<\/strong>, successfully finished its phase 1b <\/strong>clinical trial and head to a phase 2 <\/strong>study. The first tranche of data from the 14-patient trial<\/strong> comes from the first 10evaluable subjects who were given the HER-Vaxx vaccine at three doses on top of standard chemotherapy with cisplatin and fluorouracil or capecitabine. Of these, 5 individuals had a partial response, with a 30 per cent decrease or more in tumor<\/g> size from baseline scans. While 4 individuals showed disease stabilization.<\/strong><\/p>\n\n\n\n

Neurons ward off Alzheimer\u2019s disease<\/strong><\/p>\n\n\n\n

When the protein tau builds up inside the neurons of the brain, the cells become impaired and eventually die in a process that has been involved in Alzheimer\u2019s<\/a> and other neurodegenerative diseases. Neurons undergo a cellular \u201ccleaning system\u201d that is based on several proteins, including one called BAG3. The system clears tau from neurons and protects against Alzheimer\u2019s. Working with mouse neurons, the levels of BAG3 were changed inside the cells. When they increased BAG3, the neurons cleared extra tau. However, when BAG3 levels lowered, the toxic protein crippled the cells.<\/p>\n\n\n\n

Bristol-Myers,\nH3 Biomedicine discover RNA splicing drugs for cancer<\/strong><\/p>\n\n\n\n

Bristol-Myers Squibb<\/strong> is collaborating with Eisai <\/strong>spinoff H3 Biomedicine and its RNA-splicing technology. The duo will examine if new treatments based on H3\u2019s platform can elicit a stronger response against cancer or not. Under the agreement, Bristol-Myers and H3 will work on research focused on developing immune therapies for cancer using the latter\u2019sRNA-splicing platform. After that BMS will take care of the development and commercialization of selected compounds. H3 will pick up unrevealed amounts in an upfront payment, development, regulatory and sales milestones, and certain royalties, the pair said in a statement. Eisai will hold onto the option to co-develop and co-commercialize \u201ccertain compounds\u201d that come out of the partnership. <\/p>\n","protected":false},"excerpt":{"rendered":"

HER2 Vaccine Candidate Meet Phase 1b Study An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, successfully finished its phase 1b clinical trial and head to a phase 2 study. The first tranche of data from the 14-patient trial comes from the first 10evaluable subjects who were given the HER-Vaxx vaccine […]<\/p>\n","protected":false},"author":1,"featured_media":3476,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[72,2333,130,1541,2325,2334],"industry":[17225],"therapeutic_areas":[17245,17228],"class_list":["post-3828","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease","tag-australian-biotech-company","tag-bristol-myers-squibb","tag-eisai","tag-her-vaxx","tag-human-epidermal-growth-factor-receptor-2-her2","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nHER2 Drug Meets Phase 1b; Neurons ward off Alzheimer\u2019s Disease<\/title>\n<meta name=\"description\" content=\"An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, succesfully...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-84\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer\u2019s Disease\" \/>\n<meta property=\"og:description\" content=\"An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, succesfully...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-84\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-18T10:01:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09023956\/1-10428.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"746\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer\u2019s Disease","description":"An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, succesfully...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-84","og_locale":"en_US","og_type":"article","og_title":"HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer\u2019s Disease","og_description":"An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, succesfully...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-84","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-12-18T10:01:26+00:00","article_modified_time":"2021-07-24T07:27:09+00:00","og_image":[{"width":1536,"height":746,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09023956\/1-10428.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-84","url":"https:\/\/www.delveinsight.com\/blog\/notizia-84","name":"HER2 Drug Meets Phase 1b; Neurons ward off Alzheimer\u2019s Disease","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-84#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-84#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09023956\/1-10428.jpg","datePublished":"2018-12-18T10:01:26+00:00","dateModified":"2021-07-24T07:27:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"An Australian biotech company stated its Human Epidermal Growth Factor Receptor 2 (HER2) vaccine candidate, HER-Vaxx, succesfully...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-84"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-84#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09023956\/1-10428.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09023956\/1-10428.jpg","width":1536,"height":746},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09023956\/1-10428-300x146.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Australian biotech company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eisai<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HER-Vaxx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Human Epidermal Growth Factor Receptor 2 (HER2)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Australian biotech company<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb<\/span>","<span class=\"advgb-post-tax-term\">Eisai<\/span>","<span class=\"advgb-post-tax-term\">HER-Vaxx<\/span>","<span class=\"advgb-post-tax-term\">Human Epidermal Growth Factor Receptor 2 (HER2)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 18, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 18, 2018 3:31 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3828"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3828\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3476"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3828"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3828"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}